title: Influence of moclobemide on cognitive functions of nine depressed patients: pilot trial with neurophysiological and neuropsychological indices.
abstract: Quantitative electroencephalogram (QEEG) changes induced by the acute administration of moclobemide (200 mg) in patients with major depression include a transient increase in theta-activity, a slight augmentation of alpha-activity and a sustained increase in beta-activity. This QEEG profile distinguishes moclobemide from sedative antidepressants. A 42-day treatment with 400 mg/day of the drug produces a significant decrease in the late positive-complex peak latency of the event-related potentials, suggesting a positive effect on attention and cognitive functions.
authors.affiliation: Department of Psychiatry, Medical School, University of Naples, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Galderisi
authors.forename: A
authors.initials: A
authors.lastname: Mucci
authors.forename: P
authors.initials: P
authors.lastname: Bucci
authors.forename: M L
authors.initials: ML
authors.lastname: Mignone
authors.forename: M
authors.initials: M
authors.lastname: Maj
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects*; D001288:Attention / Q000187:drug effects*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D009483:Neuropsychological Tests; D010865:Pilot Projects
chemical_list: D000928:Antidepressive Agents; D001549:Benzamides; D020912:Moclobemide